Personalized cancer care: DNA profiling guides patients to best trials
NCT ID NCT02806388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tumor diagnosis and be able to provide a tissue sample.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose better treatments for cancer patients by matching them to the right clinical trials based on their tumor's genetic profile.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly benefit participants, and finding a matching trial does not guarantee the treatment will work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,500 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Oct 2011
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Any advanced cancer patient who would benefit from molecular profiling and is a potential clinical trial candidate as identified by treating physician.
- Ages
-
12 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed histological diagnosis of solid tumor * Suitable for systematic treatment and clinical trials * ECOG (Eastern cooperative oncology group) performance status \< 2 * Able to provide tumor tissue for molecular profiling * Able to understand and sign the informed consent form Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Cancer Centre, Singapore
RECRUITINGSingapore, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors